TY  - JOUR
TI  - Clinical and immunological outcomes of SARS-CoV-2 infection in patients with inborn errors of immunity receiving different brands and doses of COVID-19 vaccines
AB  - Clinical and immunological outcomes of SARS-CoV-2 infection in patients with inborn errors of immunity receiving different brands and doses of COVID-19 vaccines Introduction: Vaccines against severe acute respiratory syndrome-coronavi- rus-2 (SARS-CoV-2) provide successful control of the coronavirus-2019 (COVID-19) pandemic. The safety and immunogenicity studies are encourag- ing in patients with inborn errors of immunity (IEI); however, data about mortality outcomes and severe disease after vaccination still need to be fully addressed. Therefore, we aimed to determine the clinical and immunological outcomes of SARS-CoV-2 infection in patients with IEI who have received vac- cination. Materials and Methods: Eighty-eight patients with a broad range of molecular etiologies were studied; 45 experienced SARS-CoV-2 infection. Infection out- comes were analyzed in terms of genetic etiology, background clinical char - acteristics, and immunization history, including the type and number of doses received and the time elapsed since vaccination. In addition, anti-SARS-CoV-2 antibodies were quantified using electrochemiluminescent immunoassay. Results: Patients were immunized using one of the three regimens: inactivated (Sinovac, Coronavac®), mRNA (BNT162b2, Comirnaty®, Pfizer-Biontech), and a combination. All three regimens induced comparable anti-SARS-CoV-2 IgG levels, with no differences in the adverse events. Among 45 patients with COVID-19, 26 received a full course of vaccination, while 19 were vaccine-naive or received incomplete dosing. No patients died due to COVID-19 infection. The fully immunized group had a lower hospitalization rate (23% vs. 31.5%) and a shorter sympto- matic phase than the others. Among the fully vaccinated patients, serum IgM and E levels were significantly lower in hospitalized patients than non-hospitalized patients. Conclusion: COVID-19 vaccines were well-tolerated by the IEI patients, and a full course of immunization was associated with lower hospitalization rates and a shorter duration of COVID-19 symptoms.
AU  - Ilki, Arzu
AU  - karabiber, esra
AU  - atik, özge
AU  - Tepetam, Fatma Merve
AU  - Ergan, Bilgehan
AU  - Karakoc-Aydiner, Elif
AU  - OZEN, AHMET
AU  - Özyer, Fatma
AU  - Baris, Safa
DO  - 10.5578/tt.20239705
PY  - 2023
JO  - Tüberküloz ve Toraks
VL  - 71
IS  - 3
SN  - 0494-1373
SP  - 236
EP  - 249
DB  - TRDizin
UR  - http://search/yayin/detay/1203538
ER  -